09:44 AM EDT, 10/29/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday that it is planning a study comparing Imaavy with efgartigimod, an FcRn blocker, for patients with generalized myasthenia gravis.

The phase 3b study will determine whether treatment with Imaavy provides superior disease control versus efgartigimod, and will also include a treatment-switch arm to assess efficacy and safety of Imaavy in participants switching from efgartigimod to Imaavy, Johnson & Johnson ( JNJ ) said.

Additionally, the company said data from a Vibrance-MG phase 2/3 LTE study, in which pediatric patients were treated with Imaavy, showed 72 weeks of "sustained reduction" in immunoglobulin G and no new safety concerns.

Price: 186.36, Change: -0.56, Percent Change: -0.30